Bionovo's VG101 Shows Greater Efficacy Than Estrogen In The Treatment Of Vaginal Dryness Bionovo, Inc. (Nasdaq: BNVI) will present an abstract in a presentation on their new drug candidate, VG101, for the treatment of vaginal dryness, at the 19th Annual Meeting of the North American Menopause Society in Orlando, Florida on September 26, 2008. Dr. Mary Tagliaferri, president and chief medical officer of Bionovo, will provide seminal information on the company's second estrogen receptor beta selective drug candidate that will be entering clinical trials shortly.
Source: www.medicalnewstoday.comAnalysis Of Earlier European Stroke Trial Supports Treatment Regimen For Viprinex(TM) In Current International Phase 3 Clinical Trials Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) announced that previously found excess symptomatic intracranial hemorrhage in an earlier European trial of ancrod (now Viprinex(TM)) for the treatment of acute ischemic stroke may be minimized with avoidance of prolonged low levels of fibrinogen and use of common blood pressure entry criteria.
Source: www.medicalnewstoday.comTyverb® Demonstrates Encouraging Results In Phase II Study In Advanced Head And Neck Cancer GlaxoSmithKline's (GSK) oral targeted agent Tyverb® (lapatinib) demonstrated single agent activity and improvement in clinical response to the subsequent standard chemoradiation compared to placebo in a Phase II study of advanced squamous cell carcinoma of the head and neck (SCCHN).
Source: www.medicalnewstoday.com
# posted by Network @ 4:00 PM
